Bleeding in ACS patients has been associated with increased adverse cardiac events and negative patient outcomes. Join Dr Deepak Bhatt and panelists Drs Ehtisham Mahmud and Gabriel Steg as they discuss the treatment options and strategies to reduce bleeding in patients with ACS.

Bleeding in ACS patients has been associated with increased adverse cardiac events and negative patient outcomes. Join Drs Gilles Montalescot and Johanne Silvain as they discuss a case of bleeding and review treatment strategies to improve outcomes and minimize adverse events for these patients.

Both the US and the European Guidelines for the Management of STEMI have recently been revised to reflect new data specific to the management and treatment of STEMI patients. Join Dr E Magnus Ohman and panelists Drs Robert Harrington, Robert Storey and Jean-Pierre Bassand as they discuss the differences between the US and the European STEMI Guidelines as well as the optimal management goals for patients with STEMI.

With several new oral antiplatelet agents looming large on the horizon, don't miss this unique opportunity to hear the experts share new clinical data and analysis!

Drs Badimon, Kristensen, Spaulding and Storey explore the most appropriate treatments, based on an understanding of the intensive inhibition of platelet aggregation with dual antiplatelet therapy.

Antiplatelet therapy is the mainstay for the treatment of acute coronary syndromes (ACS). Although antiplatelet agents reduce ischemic events, "resistance" to their effects continues to occur. Join Drs Harvey White and Christian Hamm in a discussion of a clinical case of a patient that has developed resistance.

Dual antiplatelet therapy with aspirin and clopidogrel is the standard of care for patients during PCI. Even utilizing this standard, adverse clinical events do occur. This activity will review clinical data pertinent to the current state of antiplatelet therapy for the management of patients during PCI. This will include a discussion of the scope of adverse clinical events, efficacy of current antiplatet agents, antiplatelet resistance, and next-generation antiplatelet therapies, which will give attendees current and emerging treatment options for the management of patients during PCI.

Antiplatelet therapy is the mainstay for the treatment of acute coronary syndromes (ACS). Currently, there are several new investigational agents being studied to treat ACS. Please join Dr Magnus Ohman as he describes the design and rationale of their ongoing clinical trials and puts the potential impact of these future data into perspective.

Dr Topol leads a case-study based discussion with three Fellows on late stent thrombosis.

Antiplatelet therapy is an important component in the treatment of acute coronary syndromes (ACS). Join Dr Deepak Bhatt and panelists Drs Ehtisham Mahmud, Eric Peterson and Stephen Wiviott as they discuss intensifying antiplatelet therapy, stent thrombosis and the risk of early discontinuation of antiplatelet therapy.

2007 was an important year in antithrombotic therapy with the presentation of data from significant trials like TRITON-TIMI 38 and HORIZONS. Join Drs Bhatt, Wiviott and Stone as they examine these data and its role in the ever changing landscape of ACS care.

Join Drs Bhatt, Berger, and Wiviott as they discuss the PRINCIPLE-TIMI 44 trial and the rationale for intensifying antiplatelet therapy in the management of ACS patients.

Antiplatelet therapy involves a balance between the prevention of thrombosis and bleeding. The AHA 2007 Scientific Sessions program included the long-awaited results from TRITON and presentations on areas of uncertainty, including cost-effectiveness, loading dose, duration of therapy and resistance.

The use of clopidogrel and aspirin is well established in patients with acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI). However, questions still remain regarding clopidogrel efficacy due to its large interpatient variability, which may lead to potentially increased adverse clinical events (myocardial infarction and coronary-stent thrombosis). A novel thienopyridine, prasugrel, has shown less interpatient variability and more potent antiplatelet inhibition. The purpose of this program is to discuss the recent publication of the phase 3 trial involving patients with ACS with scheduled PCI, the Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38 trial. Join Dr Eric Topol and panelists, Drs Ehtisham Mahmud, Dean Kereiakes and Stephen Wiviott as they discuss these data and their applicability to clinical practice.

What are best practices when it comes to antiplatelet therapy? What happens when a patient suddenly appears resistant or nonresponsive to therapy? While guidelines provide guidance, do they catch up fast enough when new applicable data are presented and replicated? What is the latest research taking place in this fast moving environment, and how does that translate to benefits for patients in real world settings?

The use of dual antiplatelet therapy with aspirin and clopidogrel (an oral P2Y12 inhibitor) has been established for patients with acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI). However, many patients continue to have recurrent atherothrombotic events while receiving standard dual antiplatelet therapy. The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38, is a phase 3 trial involving patients with ACS and scheduled PCI, designed to compare a regimen of prasugrel (a potent oral P2Y12 inhibitor) with the standard-dose regimen of clopidogrel. Please join Drs Bates, Berger, Bhatt, Ohman, Popma, and Steg as they discuss the results from TRITON TIMI 38 and its potential implications for the treatment of patients with ACS.